Cultivation, chemistry, and genome of Psilocybe zapotecorum
Dusty R. Miller, Jordan Taylor Jacobs, Alan Rockefeller, Harte Singer, Ian M. Bollinger, James Conway, Jason C. Slot, David E. Cliffel
Journal of Psychedelic Studies April 5, 2024 DOI: 10.1556/2054.2023.00332 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 7 |
| Population | Psilocybe zapotecorum mushroom samples |
| Keywords | Computational biology Alkaloids |
| Citations | 7 |
| Key findings | Psilocybe zapotecorum has a psilocybin concentration of 17.9 ± 1.7 mg/g and a combined tryptamine concentration of 22.5 ± 3.2 mg/g, with its genome revealing the psilocybin gene cluster architecture. |
Abstract
Abstract Psilocybe zapotecorum is a strongly blue-bruising psilocybin mushroom used by indigenous groups in southeastern Mexico and beyond. While this species has a rich history of ceremonial use, research into its chemistry and genetics has been limited. Herein, we report on mushroom morphology, cultivation parameters, chemical profile, and the full genome sequence of P. zapotecorum . First, we detail growth and cloning methods that are simple, and reproducible. In combination with high resolution microscopic analysis, the strain was identified by DNA barcoding, confirming the field identification. Full genome sequencing reveals the architecture of the psilocybin gene cluster in P. zapotecorum, and can serve as a reference genome for Psilocybe clade I. Characterization of the tryptamine profile revealed a psilocybin concentration of 17.9 ± 1.7 mg/g, with a range of 10.6–25.7 mg/g ( n = 7), and similar tryptamines (psilocin, baeocystin, norbaeocystin, norpsilocin, aeruginascin, and 4-HO-tryptamine) in lesser concentrations for a combined tryptamine concentration of 22.5 ± 3.2 mg/g. These results show P. zapotecorum to be a potent and chemically variable Psilocybe mushroom. Chemical profiling, genetic analysis, and cultivation assist in demystifying these mushrooms. As clinical studies with psilocybin gain traction, understanding the diversity of Psilocybe expands the conversation beyond the molecule.
Citations in the library
Cited by 7
- Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications Pharmaceuticals March 7, 2025
- Chemical Composition and Biological Activities of Psilocybe Mushrooms: Gaps and Perspectives Pharmaceuticals July 1, 2025
- High-quality draft genomes of ecologically and geographically diverse Psilocybe species Microbiology Resource Announcements December 27, 2024
- Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review. Current microbiology July 15, 2025
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development Biomolecules July 3, 2026
and 2 more in the library
Cites 24
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin Journal of Psychopharmacology October 6, 2015
and 19 more in the library